In a bid to tap the $452-million Fexofenadine drug market, Dr Reddy's Laboratories has announced the launch of generic version of Allegra - Fexofenadine HCl - tablets in the US market. GV Prasad, CEO and Vice Chairman, of DRL said it is right time to focus on the US generics market.